학술

Neoadjuvant chemotherapy response prediction using pretreatment diffusion and contrast-enhanced magnetic resonance imaging with clinical variables

arXiv CS.AI
CC BY
이 매체는 공공·자유 라이선스로 본문을 직접 표시합니다.

Abstract

Prediction of pathological complete response before neoadjuvant chemotherapy may facilitate more tailored therapeutic planning for breast cancer patients.

This work proposes a deep-learning model for pretreatment data only, combining apparent diffusion coefficient maps, dynamic contrast-enhanced magnetic resonance imaging, and clinical variables.

The study uses the public ACRIN 6698/I-SPY2 multicenter dataset.

The architecture employs EfficientNet-B0 pretrained encoders for image feature extraction and late fusion with clinical information.

Multiple clinical variables were evaluated, including age, race, histological type, HR/HER2 subtype, SBR grade, and maximum diameter.

Only HR/HER2 subtype improved the average area under the receiver operating characteristic curve (AUC) and was retained in the final model.

Using stratified five-fold cross-validation, standalone apparent diffusion coefficient maps achieved a mean AUC of 0.79, whereas dynamic contrast-enhanced magnetic resonance imaging achieved 0.74.

Adding HR/HER2 subtype improved performance to 0.83 and 0.81, respectively.

The final configuration, using both imaging modalities and HR/HER2 subtype, achieved an AUC of 0.86.

These results support pretreatment multimodal learning for response prediction, although external validation is required before clinical use.

관련 뉴스